These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27440714)

  • 1. Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement.
    Petrucci G; Rizzi A; Cavalca V; Habib A; Pitocco D; Veglia F; Ranalli P; Zaccardi F; Pagliaccia F; Tremoli E; Patrono C; Rocca B
    Thromb Haemost; 2016 Oct; 116(5):891-896. PubMed ID: 27440714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome.
    Kawai VK; Avalos I; Oeser A; Oates JA; Milne GL; Solus JF; Chung CP; Stein CM
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):285-92. PubMed ID: 24022862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies.
    Brun C; Daali Y; Combescure C; Zufferey A; Michelson AD; Fontana P; Reny JL; Frelinger AL
    Platelets; 2016; 27(3):196-202. PubMed ID: 26270593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
    Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
    J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease.
    Giaretta A; Rocca B; Di Camillo B; Toffolo GM; Patrono C
    Clin Pharmacol Ther; 2017 Nov; 102(5):823-831. PubMed ID: 28378909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of selected pre-analytical phase variables on plasma thromboxane A₂ measurements in humans.
    Sadilkova L; Paluch Z; Mottlova J; Bednar F; Alusik S
    Int J Lab Hematol; 2013 Feb; 35(1):92-100. PubMed ID: 22908995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy.
    Sundaravadivel P; Christopher R; Ramanujam N; Chandra SR
    Thromb Res; 2021 Dec; 208():92-98. PubMed ID: 34742142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
    Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
    Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.
    Temperilli F; Rina A; Massimi I; Montemari AL; Guarino ML; Zicari A; Pulcinelli FM
    Platelets; 2015; 26(8):783-7. PubMed ID: 25734355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement.
    Zantek ND; Luepker RV; Duval S; Miller K; Oldenburg N; Hirsch AT
    Clin Appl Thromb Hemost; 2014 May; 20(4):385-92. PubMed ID: 23653145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin.
    Dudley A; Thomason J; Fritz S; Grady J; Stokes J; Wills R; Pinchuk L; Mackin A; Lunsford K
    J Vet Intern Med; 2013; 27(1):141-9. PubMed ID: 23278865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
    Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
    J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings.
    Crescente M; Cerletti C; de Gaetano G
    Thromb Haemost; 2007 Jun; 97(6):1054-6. PubMed ID: 17549313
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat.
    Livio M; Benigni A; Zoja C; Begnis R; Morelli C; Rossini M; Garattini S; Remuzzi G
    J Pharmacol Exp Ther; 1989 Jan; 248(1):334-41. PubMed ID: 2492341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.